<DOC>
	<DOCNO>NCT01390584</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin hydrochloride , bleomycin sulfate , vinblastine , dacarbazine , cyclophosphamide , etoposide , procarbazine hydrochloride , vincristine sulfate , prednisone , work different way stop growth cancer cell , either kill cell stop divide . Radiation therapy use high-energy x ray kill cancer cell . Giving combination chemotherapy together radiation therapy may kill cancer cell . Comparing result image procedure , PET scan CT scan , do , , chemotherapy may help doctor predict patient 's response treatment help plan best treatment . PURPOSE : This phase II clinical trial study well chemotherapy base PET/CT scan work treat patient stage I stage II Hodgkin lymphoma .</brief_summary>
	<brief_title>Chemotherapy Based PET Scan Treating Patients With Stage I Stage II Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate progression-free survival ( PFS ) 36 month follow registration patient positron emission tomography ( PET ) negative 2 course chemotherapy , receive 4 additional course doxorubicin hydrochloride , bleomycin sulfate , vinblastine , dacarbazine ( ABVD ) follow involved-nodal radiotherapy [ INRT ] 30-30.6 Gy . Secondary - To evaluate PET-negative rate 2 course ABVD chemotherapy patient stage I/II Hodgkin lymphoma bulky mediastinal disease . - To evaluate PFS 36 month patient PET positive 2 course chemotherapy receive 4 course escalate bleomycin sulfate , etoposide , doxorubicin hydrochloride , cyclophosphamide , vincristine sulfate , procarbazine hydrochloride , prednisone ( BEACOPP ) follow INRT 30-30.6 Gy . - To evaluate complete response ( CR ) rate overall survival ( OS ) PET-positive PET-negative patient 2 course ABVD . - To identify site relapse follow combined-modality therapy ( CMT ) patient large mediastinal adenopathy correlate RT field . - To assess toxicity arm study . - To assess reproductive function baseline 3 year ABVD escalate BEACOPP specific serum marker . - To bank serum plasma baseline select time point assess prognostic value various marker , limited , SCD30 , IL10 , CCL17 , CCL22 , MDC . - To create tissue microarrays ( TMAs ) patient tumor block future biomarker assessment include , limited , bcl-2 , FOXP3 , macrophage content . - To measure serum TARC level pre-treatment post two course ABVD correlate PET-CT finding ( performed time point ) 3 year PFS . Tertiary - To assess predictive value fludeoxyglucose F 18 ( 18FDG ) uptake , measure semi-quantitative measurement include standard uptake variable ( SUVs ) , respect response end chemotherapy PFS . - To compare predictive value response PFS FDG uptake alone FDG uptake combination CT size change information . - To compare predictive value response PFS FDG uptake alone FDG uptake combination available serum tissue molecular biomarkers . - To compare result secondary image objective correspond CALGB 50801 result ( contingent reach agreement CALGB combine analysis two study ) . OUTLINE : This multicenter study . Induction ABVD chemotherapy : Patients receive doxorubicin hydrochloride IV , bleomycin sulfate IV , vinblastine IV 3-5 minute , dacarbazine IV 30 minute day 1 15 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . Patients assign intervention arm accord fludeoxyglucose F 18 ( 18 FDG ) positron emission tomography ( PET ) /computed tomography ( CT ) result ( negative v positive ) . - ABVD ( 18FDG-PET/CT negative ) : Patients receive doxorubicin hydrochloride , bleomycin sulfate , vinblastine , dacarbazine induction chemotherapy . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . Within 3-6 week completion chemotherapy , patient undergo involved-node radiotherapy ( INRT ) 5 day week approximately 3½ week . - Escalated standard BEACOPP* ( 18FDG-PET/CT positive ) : Patients receive doxorubicin hydrochloride IV cyclophosphamide IV 60 minute day 1 , etoposide IV 60 minute day 1-3 , procarbazine hydrochloride orally ( PO ) day 1-7 , prednisone PO day 1-14 , bleomycin sulfate IV vincristine sulfate IV day 8 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Within 3-6 week completion chemotherapy , patient achieve complete response negative 18FDG-PET/CT scan undergo INRT 5 day week approximately 3½ week . NOTE : *HIV-positive patient whose 18FDG-PET/CT scan positive two course induction ABVD receive 4 course standard BEACOPP follow INRT . Patients undergo 18FDG-PET scan baseline , within 8-10 day 2 course ABVD induction chemotherapy . Patients also undergo 18FDG-PET/CT** scan within 3-8 week completion 4 course BEACOPP 6 course ABVD , 3 month completion INRT . NOTE : **If PET/CT remain positive , biopsy may perform medically appropriate clinically feasible discretion treat physician . If biopsy positive , patient follow survival secondary malignancy new primary . Patients may undergo blood sample collection correlative study . After completion study therapy , patient follow every 3 month 1 year , every 6 month 2 year , annually 10 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven classical Hodgkin lymphoma subclassified accord World Health Organization ( WHO ) Classification Tumors , 4th edition ( 2008 ) Nodular lymphocytepredominant Hodgkin lymphoma exclude Patients must clinical stage IA , IB , IIA , IIB disease Patients `` E '' extension eligible criterion meet Patients must mediastinal mass &gt; 0.33cm maximum intrathoracic diameter stand posteroanterior chest xray measure &gt; 10 cm large diameter axial CT image Bone marrow biopsy require PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,000/μL Platelet count ≥ 100,000/μL Hemoglobin ≥ 10 g/dL Serum creatinine ≤ 2 mg/dL Direct bilirubin ≤ 2 mg/dL AST/ALT ≤ 2 time upper limit normal Not pregnant nursing Negative pregnancy test Women childbearing potential sexually active male must strongly advise use accept effective method contraception No `` currently active '' second malignancy nonmelanoma skin cancer Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse LVEF ECHO MUGA normal unless thought disease relate DLCO ≥ 60 % symptomatic pulmonary disease unless think disease related Patients history intravenous drug abuse , behavior associate increase risk HIV infection , test exposure HIV virus , HIV test require entry protocol HIVpositive patient eligible CD4 count ≥ 400/mm³ concurrent antiretrovirals Patient HIV status must know prior registration HIVpositive patient must multidrug resistant HIV infection ; CD4 count &lt; 400/mm³ ; concurrent AIDSdefining condition PRIOR CONCURRENT THERAPY : No prior treatment ( chemotherapy radiation therapy ) Hodgkin lymphoma Concurrent antiretroviral therapy HIVpositive patient ( CD4 count ≥ 400/mm³ ) allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>adult favorable prognosis Hodgkin lymphoma</keyword>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>adult unfavorable prognosis Hodgkin lymphoma</keyword>
</DOC>